Key features and details
- Rabbit polyclonal to Osteoprotegerin
- Suitable for: IHC-P, WB
- Reacts with: Mouse, Rat
- Isotype: IgG
Product nameAnti-Osteoprotegerin antibody
See all Osteoprotegerin primary antibodies
DescriptionRabbit polyclonal to Osteoprotegerin
Tested applicationsSuitable for: IHC-P, WBmore details
Species reactivityReacts with: Mouse, Rat
Predicted to work with: Human
- IHC-P: Rat tibia and mouse bone tissues.
Storage instructionsShipped at 4°C. Store at +4°C short term (1-2 weeks). Upon delivery aliquot. Store at -20°C long term. Avoid freeze / thaw cycle.
Storage bufferPreservative: 0.09% Sodium azide
Constituents: 50% Glycerol, 1% BSA
Concentration information loading...
PurityProtein A purified
Our Abpromise guarantee covers the use of ab203061 in the following tested applications.
The application notes include recommended starting dilutions; optimal dilutions/concentrations should be determined by the end user.
|IHC-P||1/100 - 1/500. Perform heat mediated antigen retrieval with citrate buffer pH 6 before commencing with IHC staining protocol.|
FunctionActs as decoy receptor for RANKL and thereby neutralizes its function in osteoclastogenesis. Inhibits the activation of osteoclasts and promotes osteoclast apoptosis in vitro. Bone homeostasis seems to depend on the local RANKL/OPG ratio. May also play a role in preventing arterial calcification. May act as decoy receptor for TRAIL and protect against apoptosis. TRAIL binding blocks the inhibition of osteoclastogenesis.
Tissue specificityHighly expressed in adult lung, heart, kidney, liver, spleen, thymus, prostate, ovary, small intestine, thyroid, lymph node, trachea, adrenal gland, testis, and bone marrow. Detected at very low levels in brain, placenta and skeletal muscle. Highly expressed in fetal kidney, liver and lung.
Involvement in diseaseDefects in TNFRSF11B are the cause of juvenile Paget disease (JPD) [MIM:239000]; also known as hyperostosis corticalis deformans juvenilis or hereditary hyperphosphatasia or chronic congenital idiopathic hyperphosphatasia. JPD is a rare autosomal recessive osteopathy that presents in infancy or early childhood. The disorder is characterized by rapidly remodeling woven bone, osteopenia, debilitating fractures, and deformities due to a markedly accelerated rate of bone remodeling throughout the skeleton. Approximately 40 cases of JPD have been reported worldwide. Unless it is treated with drugs that block osteoclast-mediated skeletal resorption, the disease can be fatal.
Sequence similaritiesContains 2 death domains.
Contains 4 TNFR-Cys repeats.
modificationsN-glycosylated. Contains sialic acid residues.
The N-terminus is blocked.
- Information by UniProt
- MGC29565 antibody
- OCIF antibody
- OPG antibody
All lanes : Anti-Osteoprotegerin antibody (ab203061) at 1/300 dilution
Lane 1 : Mouse heart lysates
Lane 2 : Mouse kidney lysates
All lanes : Conjugated secondary antibody at 1/20000 dilution
Immunohistochemical analysis of formalin-fixed paraffin-embedded rat tibia tissue, labeling Osteoprotegerin using ab203061 at a 1/200 dilution, followed by conjugation to the secondary antibody and DAB staining.
Immunohistochemical analysis of formalin-fixed paraffin-embedded mouse bone (decalcified in EDTA), labeling Osteoprotegerin using ab203061 at a 1/100 dilution, followed by conjugation to the secondary antibody and DAB staining.
ab203061 has been referenced in 2 publications.
- Li Y et al. Bone marrow macrophage M2 polarization and adipose-derived stem cells osteogenic differentiation synergistically promote rehabilitation of bone damage. J Cell Biochem 120:19891-19901 (2019). PubMed: 31338874
- He XF et al. Berberine alleviates oxidative stress in rats with osteoporosis through receptor activator of NF-kB/receptor activator of NF-kB ligand/osteoprotegerin (RANK/RANKL/OPG) pathway. Bosn J Basic Med Sci 17:295-301 (2017). PubMed: 29055350